EP3326932A1 - Closure system for bottles containing lyophilized or liquid products, particularly injectable or perfusable pharmaceutical products - Google Patents
Closure system for bottles containing lyophilized or liquid products, particularly injectable or perfusable pharmaceutical products Download PDFInfo
- Publication number
- EP3326932A1 EP3326932A1 EP17194211.3A EP17194211A EP3326932A1 EP 3326932 A1 EP3326932 A1 EP 3326932A1 EP 17194211 A EP17194211 A EP 17194211A EP 3326932 A1 EP3326932 A1 EP 3326932A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- capsule
- closure system
- inner capsule
- bottle
- closure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012263 liquid product Substances 0.000 title claims abstract description 8
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 8
- 229940127557 pharmaceutical product Drugs 0.000 title claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 128
- 239000004033 plastic Substances 0.000 claims description 9
- 238000001746 injection moulding Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 13
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 9
- 229910052782 aluminium Inorganic materials 0.000 description 9
- 239000004411 aluminium Substances 0.000 description 9
- 230000008901 benefit Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D51/00—Closures not otherwise provided for
- B65D51/002—Closures to be pierced by an extracting-device for the contents and fixed on the container by separate retaining means
Definitions
- the present invention relates to a closure system for bottles containing lyophilized or liquid products, particularly injectable or perfusable pharmaceutical products.
- Bottles or vials containing pharmaceutical products such as lyophilized or liquid products for injection or perfusion are generally closed by means of a perforable rubber plug, for example by means of a needle, held on the neck of the bottle by means of an aluminium capsule that completely covers the rubber plug.
- the aluminium capsules generally have a portion that may be removed by tearing, which allows access to the rubber plug.
- aluminium capsules consists in the fact that the steps of mounting the capsule on the rubber plug and on the neck of the bottle cannot be executed in conditions of sterilisation and the absence of undesired particles because the folding and cutting operations of the aluminium sheets for making the capsules and the mounting thereof on the mouth of the bottle involve the generation of aluminium powders which are incompatible with the conditions of sterilisation and the absence of undesired particles required for the type of products contained in the bottle itself.
- Such aluminium capsules make it therefore difficult to minimise the level of particle contamination admitted into controlled-atmosphere environments, such as a cleanroom.
- capsules made of plastic often are not capable of supporting the temperatures that can be reached in autoclave sterilisation processes, which may reach up to 140°C, or in any case they undergo deformations such as to put at risk the sterilisation conditions of the bottle itself.
- the plastic capsules In order to resist the sterilisation processes, the plastic capsules must have more rigid structures that require a significant force of application in order to be mounted securely on the neck of the bottle, which force of application cannot generally be obtained with normal capsuling machines.
- the implementation of capsuling machines with increased force of application results in a significant increase of the set-up costs of the processing plant. Moreover, the use of an increased force could result in problems of the bottles or the capsules themselves breaking.
- Plastic capsules are also known that have several and numerous components mutually assembled with one another in various operations which however, on the one hand do not ensure an adequate resistance to the autoclave sterilisation, and on the other hand, result in an apparent increase of the production and assembly times and costs of the capsule itself.
- the closure system for bottles containing lyophilized or liquid products particularly injectable or perfusable pharmaceutical products, indicated as a whole with reference number 1, comprises:
- the outer capsule 15 is made in a single body and comprises an upper disc-shaped portion 17 configured to close the opening 13 of the inner capsule 9 and a lower portion 19 able to be fitted around the inner capsule 9. Moreover, according to the invention, the outer capsule 15 comprises a breaking line 21 between the upper disc-shaped portion 17 and the lower portion 19.
- the outer capsule 15 closes and covers the inner capsule 9 both at the top and at the sides.
- the inner capsule 9 comprises, on its lateral surface, a plurality of through-openings 33.
- the lower portion 19 of the outer capsule 15 is fitted around the inner capsule 9, and preferably is fitted around the inner capsule 9 so as to completely cover the side thereof, and in particular the lateral through-openings 33.
- the outer capsule 15 is fitted around the inner capsule 9 with interference so that the outer capsule 15 and the inner capsule 9 define a single body capable of giving resistance to the forces that develop, for example during the autoclave sterilisation.
- the outer capsule 15 is made of a material of the plastic type through injection moulding.
- the outer capsule 15 is made of a material of the polypropylene type.
- the breaking line 21 comprises a plurality of bridges 23 made through the aforesaid injection moulding.
- the outer capsule 15 may be made in a single injection moulding step together also with the bridges 23.
- the breaking line 21 may comprise a weakened line defined by an incision, or partial cut, of the outer capsule 15 executed in a step successive to the one of the injection moulding of the outer capsule 15 itself.
- the breaking line 21 allows easily separating the upper disc-shaped portion 17 of the outer capsule 15 from the lower portion 19 fitted around the inner capsule 9. This allows exposing the opening 13 of the inner capsule 9 and allows the access and perforation, for example by means of a needle, of the closure body 3.
- the lower portion 19 of the outer capsule 15 may comprise, substantially at the breaking line 21, a band 25 having a radial thickness substantially less than the radial thickness of the remaining part of the lower portion 19.
- the lower portion 19 of the outer capsule 15 comprises, substantially at the breaking line 21, a band 25 having a radial thickness that narrows in the axial direction 27 of approach to the breaking line 21.
- the reduction of the thickness of the wall of the outer capsule 15 at the breaking line 21 further facilitates the separation of the upper disc-shaped portion 17 from the lower portion 19.
- the upper disc-shaped portion 17 may be raised upwards and pulled off from the lower portion 19 by acting with the fingertip on the lower perimeter edge 24 of the upper disc-shaped portion 17 itself, which edge 24 is exposed with respect to the lateral wall of the lower portion 19, due to the narrowing of the thickness thereof approaching the breaking line 21.
- breaking line 21 were defined by a plurality of bridges 23, the rotation of the upper disc-shaped portion 17 with respect to the central axis 27 would produce the same separating effect of the upper disc-shaped portion 17 with respect to the lower portion 19 because it would cause the breaking of the bridges 23 themselves.
- the inner capsule 9 comprises a plurality of elastically deformable tabs 29 projecting radially towards the inside of the inner capsule 9 itself. Such tabs 29 are configured to engage with the finish 31 of the bottle 7.
- the tabs 29 are obtained at the through-openings 33 on the lateral surface of the inner capsule 9.
- the tabs 29 are preferably equally distributed angularly around the central axis 27.
- the inner capsule 9 is made of a material of the plastic type, and preferably of the polycarbonate type, through injection moulding.
- the through-openings 33 obtained at the tabs 29 allow facilitating the removal of the tabs 29 themselves from the injection mould.
- the tabs 29 allow the inner capsule 9 to hold the closure body 3 in a sealed closure configuration against the mouth 5 of the bottle 7.
- the tabs 29 are elastically deformable, also due to the presence of the through-openings 33, allows easily fitting the inner capsule 9 on the neck 11 of the bottle 7. Indeed, in step of pressure applying the inner capsule 9 onto the neck 11 of the bottle 7, the finish 31 exerts a force in horizontal direction on the tabs 29 themselves, which force deforms the tabs 29 radially outwards until they exceed the finish 31. Once they have exceeded the finish 31, the tabs 29 may return to their rest configuration projecting radially towards the inside of the inner capsule 9, in which configuration they engage at the bottom with the finish 31 of the bottle 7.
- the portion of cylindrical wall 54 of the inner capsule 9 which lies at the bottom of the tabs 29 has an increased cross-section with respect to the cross-section of the overlying tabs 29.
- the resistance is ensured to the forces which develop during the autoclave sterilisation.
- the tabs 29 project radially towards the inside of the inner capsule 9 itself with an inclination which is less than or equal 30° with respect to the underlying portion of cylindrical wall 54, that is with respect to the vertical direction.
- the closure body 3 may be a rubber gasket 30, as shown in figures 4 and 9 , or a rubber plug 32 as shown in figures 5 and 10 .
- the rubber gasket 30 and the rubber plug 32 are advantageously held at the top against the mouth 5 of the bottle 7 by the inner capsule 9.
- the rubber plug 32 also has a lower portion which is inserted, with interference, into the mouth 5 of the bottle 7.
- the tabs 29 are adapted to hold the closure body 3 on the mouth 5 of the bottle 7, thus ensuring the seal of the liquid contained inside the bottle 7, also under the action of the internal pressure generated during the autoclave sterilisation treatment.
- the lower portion 19 of the outer capsule 15 comprises at least one rib 35 projecting radially towards the inside of the outer capsule 15, configured to engage in a corresponding seat 37 obtained on the outer surface of the inner capsule 9.
- At least two ribs 35 and two corresponding seats 37 are provided at least two ribs 35 and two corresponding seats 37.
- the ribs 35 develop circumferentially around the whole lower portion 19 of the outer capsule 15, like the corresponding seats 37 develop circumferentially around the whole outer surface of the inner capsule 9.
- the inner capsule 9 may comprise a rib 45 projecting radially towards the inside of the capsule configured to hold, by interference, the closure body 3.
- rib 45 develops circumferentially around the whole inner capsule 9.
- the outer capsule 15, inner capsule 9 and closure body 3 assembly define an assembly that can be handled as though it were a single body.
- the disc-shaped upper portion 17 may comprise, at its face that faces the opening 13 of the inner capsule 9, a cylindrical wall 41 axially protruding towards the edge 39 of the opening 13 and configured to engage with such edge 39.
- the cylindrical wall 41 ensures the centring of the disc-shaped upper portion 17 of the outer capsule 15 with respect to the edge 39 of the opening 13.
- the disc-shaped upper portion 17 of the outer capsule 15 may comprise, at its face facing the opening 13 of the inner capsule 9, a plurality of tabs 38 axially projecting towards the edge 39 of the opening 13 and configured to engage with such edge 39.
- the tabs 38 are also folded around the edge 39 of the opening 13, for example in assembly step between the outer capsule 15 and the inner capsule 9.
- such coupling provides the upper disc-shaped portion 17 with increased resistance to the internal pressure that is generated in vertical direction in the bottle 7, and therefore increased resistance to the push that acts on the closure body 3 during the autoclave sterilisation treatment.
- the closure system 1 comprises a tamper-evident ring 43 associated with the outer capsule 15.
- the tamper-evident ring 43 is advantageously associated with the lower edge of the outer capsule 15 by means of a plurality of bridges 49.
- the tamper-evident ring 43 comprises advantageously an undercut 51 configured to engage with the lower edge 53 of the inner capsule 9.
- the tamper-evident ring 43 serves the purposes of emphasizing any attempts to tamper with the closure system 1.
- the operator When the bottle 7 is used, the operator, or patient, lifts the edge 24 of the upper disc-shaped portion 17 of the outer capsule 15 with his/her fingertip, thus breaking any bridges 23 that join such upper portion to the lower portion 19 and removing the tabs 38, or the circular wall 41, from the edge 39 of the opening 13 of the inner capsule 9.
- the opening 13 of the inner capsule 9 is exposed and it is possible to perforate the closure body 3 with a needle at the opening 13 of the inner capsule 9 to introduce it into the mouth 5 of the bottle 7 in order to suck the liquid contained in the bottle 7.
- the closure system object of the present invention has the advantage of being made completely of a material of the plastic type and of being pressure applied onto the bottles, without generating powders that are incompatible with the sterility requirements of the product contained in the bottle itself, as instead happens in the case of closure systems at least partially made of aluminium.
- Another advantage of the invention consists in the fact that the outer capsule, inner capsule and closure body assembly may be applied as though they were a single body, in a single step, to the bottle, directly in the cleanroom, immediately after the filling of the bottle with the product required.
- the application of the aforesaid assembly may also be executed in completely automated manner.
- Another advantage again of the invention consists in the fact that the tabs on the inner capsule on the one hand, allow the closure system to resist in a satisfactory manner to the stresses generated during the autoclave sterilisation process, and on the other hand, to be easily pressure applied to the neck of the bottle.
- a further advantage of the closure system according to the invention consists in the fact of being made in a minimum number of pieces that are easy to assemble with one another, that is rubber outer capsule, inner capsule and closure body.
- closure system has multiple elements that may emphasize possible tampering therewith, such as for example the bridges of the outer capsule or the bridges that connect the outer capsule to the tamper-evident ring.
- closure system thus conceived is susceptible to many modifications and variants, all falling within the invention; moreover, all the details can be replaced by technically equivalent elements.
- materials used, as well as their sizes, can be of any type according to the technical requirements.
Landscapes
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Closures For Containers (AREA)
- Medicinal Preparation (AREA)
Abstract
- a perforable closure body (3) adapted to close the mouth (5) of a bottle (7);
- an inner capsule (9), able to be fitted onto the neck (11) of the bottle (7), configured to hold the closure body (3) in a sealed closure configuration of the mouth (5) of the bottle (7), in which the inner capsule (9) comprises an opening (13) adapted for allowing access to the closure body (3);
- an outer capsule (15), able to be fitted onto the inner capsule (9).
Description
- The present invention relates to a closure system for bottles containing lyophilized or liquid products, particularly injectable or perfusable pharmaceutical products.
- Bottles or vials containing pharmaceutical products such as lyophilized or liquid products for injection or perfusion are generally closed by means of a perforable rubber plug, for example by means of a needle, held on the neck of the bottle by means of an aluminium capsule that completely covers the rubber plug. The aluminium capsules generally have a portion that may be removed by tearing, which allows access to the rubber plug.
- The main drawback of aluminium capsules consists in the fact that the steps of mounting the capsule on the rubber plug and on the neck of the bottle cannot be executed in conditions of sterilisation and the absence of undesired particles because the folding and cutting operations of the aluminium sheets for making the capsules and the mounting thereof on the mouth of the bottle involve the generation of aluminium powders which are incompatible with the conditions of sterilisation and the absence of undesired particles required for the type of products contained in the bottle itself. Such aluminium capsules make it therefore difficult to minimise the level of particle contamination admitted into controlled-atmosphere environments, such as a cleanroom.
- Another drawback of aluminium capsules consists in the fact that the operator who removes the removable portion risks being injured with the sharp edges of the aluminium sheet.
- On the other hand, also the use of capsules made of materials of the plastic type are not free from drawbacks.
- In particular, capsules made of plastic often are not capable of supporting the temperatures that can be reached in autoclave sterilisation processes, which may reach up to 140°C, or in any case they undergo deformations such as to put at risk the sterilisation conditions of the bottle itself. In order to resist the sterilisation processes, the plastic capsules must have more rigid structures that require a significant force of application in order to be mounted securely on the neck of the bottle, which force of application cannot generally be obtained with normal capsuling machines. The implementation of capsuling machines with increased force of application results in a significant increase of the set-up costs of the processing plant. Moreover, the use of an increased force could result in problems of the bottles or the capsules themselves breaking.
- Plastic capsules are also known that have several and numerous components mutually assembled with one another in various operations which however, on the one hand do not ensure an adequate resistance to the autoclave sterilisation, and on the other hand, result in an apparent increase of the production and assembly times and costs of the capsule itself.
- It is the object of the present invention to make a closure system for bottles containing lyophilized or liquid products, particularly injectable or perfusable pharmaceutical products, that is easier to make and mount on bottles, and therefore is more economically competitive when compared to the known technique, and in particular to the plastic capsule.
- It is another object of the present invention to make a closure system for bottles that does not result in the formation of powder during the mounting on the bottles.
- It is another object of the present invention to make a closure system that is capable of providing the amplest guarantees of reliability and safety in use.
- It is another object of the present invention to make a closure system that allows the bottle to be subjected to autoclave sterilisation procedures.
- These objects according to the present invention are achieved by making a closure system for bottles containing lyophilized or liquid products, particularly injectable or perfusable pharmaceutical products, as disclosed in
claim 1. - Further features are provided in the dependent claims.
- Further features and advantages shall be more apparent from the description of two preferred, but not exclusive, embodiments of a closure system for bottles, illustrated as an example and not for limiting purposes with reference to the accompanying drawings, in which:
-
figure 1 is a front view of a bottle provided with a first embodiment of a closure system, according to the invention; -
figure 2 is a perspective view of the outer capsule of the closure system illustrated infigure 1 , according to the invention; -
figure 3 is a perspective view of the inner capsule of the closure system illustrated infigure 1 ; -
figure 4 is a front sectional view of the closure system offigure 1 , according to the invention; -
figure 5 is a front sectional view of a variant of the closure system illustrated infigure 1 , according to the invention; -
figure 6 is a perspective view of a variant of the inner capsule of the closure system illustrated infigure 1 or infigure 7 , according to the invention; -
figure 7 is a front view of a bottle provided with a second embodiment of a closure system, according to the invention; -
figure 8 is a perspective view of the outer capsule of the closure system illustrated infigure 7 , according to the invention; -
figure 9 is a front sectional view of the closure system offigure 7 , according to the invention; -
figure 10 is a front sectional view of a variant of the closure system illustrated infigure 7 , according to the invention. - With reference to the mentioned drawings, the closure system for bottles containing lyophilized or liquid products, particularly injectable or perfusable pharmaceutical products, indicated as a whole with
reference number 1, comprises: - a
perforable closure body 3 adapted to close themouth 5 of abottle 7; - an
inner capsule 9, able to be fitted onto theneck 11 of thebottle 7, configured to hold theclosure body 3 in a sealed closure configuration of themouth 5 of thebottle 7, in which theinner capsule 9 comprises anopening 13 adapted for allowing access to theclosure body 3; - an
outer capsule 15, able to be fitted onto theinner capsule 9. - According to the invention, the
outer capsule 15 is made in a single body and comprises an upper disc-shapedportion 17 configured to close theopening 13 of theinner capsule 9 and alower portion 19 able to be fitted around theinner capsule 9. Moreover, according to the invention, theouter capsule 15 comprises abreaking line 21 between the upper disc-shaped portion 17 and thelower portion 19. - As shown in the accompanying drawings, advantageously the
outer capsule 15 closes and covers theinner capsule 9 both at the top and at the sides. - Advantageously, the
inner capsule 9 comprises, on its lateral surface, a plurality of through-openings 33. - Advantageously, the
lower portion 19 of theouter capsule 15 is fitted around theinner capsule 9, and preferably is fitted around theinner capsule 9 so as to completely cover the side thereof, and in particular the lateral through-openings 33. - Advantageously, the
outer capsule 15 is fitted around theinner capsule 9 with interference so that theouter capsule 15 and theinner capsule 9 define a single body capable of giving resistance to the forces that develop, for example during the autoclave sterilisation. - Advantageously, the
outer capsule 15 is made of a material of the plastic type through injection moulding. - Preferably, the
outer capsule 15 is made of a material of the polypropylene type. - Advantageously, the
breaking line 21 comprises a plurality ofbridges 23 made through the aforesaid injection moulding. - In particular, the
outer capsule 15 may be made in a single injection moulding step together also with thebridges 23. - Alternatively, or additionally, the
breaking line 21 may comprise a weakened line defined by an incision, or partial cut, of theouter capsule 15 executed in a step successive to the one of the injection moulding of theouter capsule 15 itself. - The
breaking line 21 allows easily separating the upper disc-shaped portion 17 of theouter capsule 15 from thelower portion 19 fitted around theinner capsule 9. This allows exposing theopening 13 of theinner capsule 9 and allows the access and perforation, for example by means of a needle, of theclosure body 3. - The
lower portion 19 of theouter capsule 15 may comprise, substantially at thebreaking line 21, aband 25 having a radial thickness substantially less than the radial thickness of the remaining part of thelower portion 19. - Advantageously, as shown in the accompanying drawings, the
lower portion 19 of theouter capsule 15 comprises, substantially at thebreaking line 21, aband 25 having a radial thickness that narrows in theaxial direction 27 of approach to thebreaking line 21. - The reduction of the thickness of the wall of the
outer capsule 15 at thebreaking line 21 further facilitates the separation of the upper disc-shaped portion 17 from thelower portion 19. - In particular, the upper disc-
shaped portion 17 may be raised upwards and pulled off from thelower portion 19 by acting with the fingertip on thelower perimeter edge 24 of the upper disc-shaped portion 17 itself, whichedge 24 is exposed with respect to the lateral wall of thelower portion 19, due to the narrowing of the thickness thereof approaching thebreaking line 21. - If the
breaking line 21 were defined by a plurality ofbridges 23, the rotation of the upper disc-shaped portion 17 with respect to thecentral axis 27 would produce the same separating effect of the upper disc-shapedportion 17 with respect to thelower portion 19 because it would cause the breaking of thebridges 23 themselves. - Advantageously, the
inner capsule 9 comprises a plurality of elasticallydeformable tabs 29 projecting radially towards the inside of theinner capsule 9 itself.Such tabs 29 are configured to engage with thefinish 31 of thebottle 7. - Advantageously, the
tabs 29 are obtained at the through-openings 33 on the lateral surface of theinner capsule 9. - The
tabs 29 are preferably equally distributed angularly around thecentral axis 27. - Advantageously, also the
inner capsule 9 is made of a material of the plastic type, and preferably of the polycarbonate type, through injection moulding. - The through-
openings 33 obtained at thetabs 29 allow facilitating the removal of thetabs 29 themselves from the injection mould. - Moreover, by engaging with the
finish 31 of thebottle 7, thetabs 29 allow theinner capsule 9 to hold theclosure body 3 in a sealed closure configuration against themouth 5 of thebottle 7. - The fact that the
tabs 29 are elastically deformable, also due to the presence of the through-openings 33, allows easily fitting theinner capsule 9 on theneck 11 of thebottle 7. Indeed, in step of pressure applying theinner capsule 9 onto theneck 11 of thebottle 7, thefinish 31 exerts a force in horizontal direction on thetabs 29 themselves, which force deforms thetabs 29 radially outwards until they exceed thefinish 31. Once they have exceeded thefinish 31, thetabs 29 may return to their rest configuration projecting radially towards the inside of theinner capsule 9, in which configuration they engage at the bottom with thefinish 31 of thebottle 7. - Advantageously, the portion of
cylindrical wall 54 of theinner capsule 9 which lies at the bottom of thetabs 29 has an increased cross-section with respect to the cross-section of theoverlying tabs 29. Thereby, the resistance is ensured to the forces which develop during the autoclave sterilisation. - Advantageously, the
tabs 29 project radially towards the inside of theinner capsule 9 itself with an inclination which is less than or equal 30° with respect to the underlying portion ofcylindrical wall 54, that is with respect to the vertical direction. Thereby, the resistance is further ensured to the forces which develop during the autoclave sterilisation. Theclosure body 3 may be arubber gasket 30, as shown infigures 4 and9 , or arubber plug 32 as shown infigures 5 and10 . - The
rubber gasket 30 and therubber plug 32 are advantageously held at the top against themouth 5 of thebottle 7 by theinner capsule 9. - The
rubber plug 32 also has a lower portion which is inserted, with interference, into themouth 5 of thebottle 7. - Advantageously, the
tabs 29 are adapted to hold theclosure body 3 on themouth 5 of thebottle 7, thus ensuring the seal of the liquid contained inside thebottle 7, also under the action of the internal pressure generated during the autoclave sterilisation treatment. - The
lower portion 19 of theouter capsule 15 comprises at least onerib 35 projecting radially towards the inside of theouter capsule 15, configured to engage in acorresponding seat 37 obtained on the outer surface of theinner capsule 9. - Preferably, there are provided at least two
ribs 35 and twocorresponding seats 37. - Advantageously, the
ribs 35 develop circumferentially around the wholelower portion 19 of theouter capsule 15, like thecorresponding seats 37 develop circumferentially around the whole outer surface of theinner capsule 9. - Thereby, when the
outer capsule 15 is fitted onto theinner capsule 9, the two components are firmly constrained to each other and define an assembly that can be handled as though it were a single body. - Advantageously, the
inner capsule 9 may comprise arib 45 projecting radially towards the inside of the capsule configured to hold, by interference, theclosure body 3. Preferably,such rib 45 develops circumferentially around the wholeinner capsule 9. - Due to the holding by interference of the
closure body 3 by theinner capsule 9, theouter capsule 15,inner capsule 9 andclosure body 3 assembly define an assembly that can be handled as though it were a single body. - As shown in
figures 5 and10 , alternatively to thetabs 38, the disc-shapedupper portion 17 may comprise, at its face that faces theopening 13 of theinner capsule 9, acylindrical wall 41 axially protruding towards theedge 39 of theopening 13 and configured to engage withsuch edge 39. - The
cylindrical wall 41 ensures the centring of the disc-shapedupper portion 17 of theouter capsule 15 with respect to theedge 39 of theopening 13. - As shown instead in
figures 4 and9 , the disc-shapedupper portion 17 of theouter capsule 15 may comprise, at its face facing theopening 13 of theinner capsule 9, a plurality oftabs 38 axially projecting towards theedge 39 of theopening 13 and configured to engage withsuch edge 39. - Advantageously, the
tabs 38 are also folded around theedge 39 of theopening 13, for example in assembly step between theouter capsule 15 and theinner capsule 9. - The engagement of the
tabs 38 of theouter capsule 15 with theedge 39 of theopening 13 of theinner capsule 9 further stabilizes the coupling betweeninner capsule 9 andouter capsule 15. - In particular, such coupling provides the upper disc-shaped
portion 17 with increased resistance to the internal pressure that is generated in vertical direction in thebottle 7, and therefore increased resistance to the push that acts on theclosure body 3 during the autoclave sterilisation treatment. - The presence of the
tabs 38 or of thecylindrical wall 41 does not however prevent the separation of the upper disc-shapedportion 17 of theouter capsule 15 from thelower portion 19 becausesuch tabs 38, or suchcylindrical wall 41, are removed from theedge 39 of theopening 13 when the upper disc-shapedportion 17 of theouter capsule 15 is removed. - In the variant of
inner capsule 9 illustrated infigure 6 , there are advantageously provided a plurality ofbodies 47 projecting axially and radially towards the inside of thecapsule 9, which are configured to hold theclosure body 3 in theinner capsule 9. - In the embodiment illustrated in
figures 7 to 10 , theclosure system 1 comprises a tamper-evident ring 43 associated with theouter capsule 15. The tamper-evident ring 43 is advantageously associated with the lower edge of theouter capsule 15 by means of a plurality ofbridges 49. - The tamper-
evident ring 43 comprises advantageously an undercut 51 configured to engage with thelower edge 53 of theinner capsule 9. - The tamper-
evident ring 43 serves the purposes of emphasizing any attempts to tamper with theclosure system 1. - When the
bottle 7 is used, the operator, or patient, lifts theedge 24 of the upper disc-shapedportion 17 of theouter capsule 15 with his/her fingertip, thus breaking anybridges 23 that join such upper portion to thelower portion 19 and removing thetabs 38, or thecircular wall 41, from theedge 39 of theopening 13 of theinner capsule 9. - Thereby, the
opening 13 of theinner capsule 9 is exposed and it is possible to perforate theclosure body 3 with a needle at theopening 13 of theinner capsule 9 to introduce it into themouth 5 of thebottle 7 in order to suck the liquid contained in thebottle 7. - The closure system object of the present invention has the advantage of being made completely of a material of the plastic type and of being pressure applied onto the bottles, without generating powders that are incompatible with the sterility requirements of the product contained in the bottle itself, as instead happens in the case of closure systems at least partially made of aluminium.
- Another advantage of the invention consists in the fact that the outer capsule, inner capsule and closure body assembly may be applied as though they were a single body, in a single step, to the bottle, directly in the cleanroom, immediately after the filling of the bottle with the product required. The application of the aforesaid assembly may also be executed in completely automated manner.
- Another advantage again of the invention consists in the fact that the tabs on the inner capsule on the one hand, allow the closure system to resist in a satisfactory manner to the stresses generated during the autoclave sterilisation process, and on the other hand, to be easily pressure applied to the neck of the bottle.
- A further advantage of the closure system according to the invention consists in the fact of being made in a minimum number of pieces that are easy to assemble with one another, that is rubber outer capsule, inner capsule and closure body.
- The fact that the number of separate components of the closure system is minimised makes both the production of the closure system and its assembly on the bottle more economical and quicker.
- Another advantage again of the invention consists in the fact that the closure system has multiple elements that may emphasize possible tampering therewith, such as for example the bridges of the outer capsule or the bridges that connect the outer capsule to the tamper-evident ring.
- The closure system thus conceived is susceptible to many modifications and variants, all falling within the invention; moreover, all the details can be replaced by technically equivalent elements. In practice, the materials used, as well as their sizes, can be of any type according to the technical requirements.
Claims (11)
- Closure system (1) for bottles containing lyophilized or liquid products, particularly injectable or perfusable pharmaceutical products, comprising:- a perforable closure body (3) adapted for closing the mouth (5) of a bottle (7);- an inner capsule (9), able to be fitted onto the neck (11) of said bottle (7), configured to hold said closure body (3) in a sealed closure configuration of said mouth (5) of said bottle (7), said inner capsule (9) comprising an opening (13) adapted for allowing access to said closure body (3);- an outer capsule (15), able to be fitted onto said inner capsule (9);characterised in that said outer capsule (15) is made in a single body and comprises an upper disc-shaped portion (17) configured to close said opening (13) of said inner capsule (9) and a lower portion (19) able to be fitted around said inner capsule (9), said outer capsule (15) comprising a breaking line (21) between said upper disc-shaped portion (17) and said lower portion (19).
- Closure system (1), according to claim 1, characterised in that said outer capsule (15) is made of a material of the plastic type through injection moulding.
- Closure system (1), according to claim 1 or 2, characterised in that said breaking line (21) comprises a plurality of bridges (23) made through said injection moulding.
- Closure system (1), according to claim 1 or 2, characterised in that said breaking line (21) comprises a weakened line made through incision following said injection moulding.
- Closure system (1), according to one or more of the previous claims, characterised in that said lower portion (19) of said outer capsule (15) comprises, substantially at said breaking line (21), a band (25) having a radial thickness substantially less than the radial thickness of the remaining part of said lower portion (19).
- Closure system (1), according to one or more of the previous claims, characterised in that said lower portion (19) of said outer capsule (15) comprises, substantially at said breaking line (21), a band (25) having a radial thickness that narrows in the axial direction (27) of approach to said breaking line (21).
- Closure system (1), according to one or more of the previous claims, characterised in that said inner capsule (9) comprises a plurality of elastically deformable tabs (29) projecting radially towards the inside of said inner capsule (9), said tabs (29) being configured to engage with the bottle finish (31) of said bottle (7), said tabs (29) being obtained at through-openings (33) present on the lateral surface of said inner capsule (9).
- Closure system (1), according to one or more of the previous claims, characterised in that said lower portion (19) of said outer capsule (15) comprises at least one rib (35) projecting radially towards the inside of said outer capsule (15) configured to engage in a corresponding seat (37) obtained on the outer surface of said inner capsule (9).
- Closure system (1), according to one or more of the previous claims, characterised in that said disc-shaped upper portion (17) comprises, at its face that faces said opening (13) of said inner capsule (9), a cylindrical wall (41) projecting axially towards the edge (39) of said opening (13) and configured to engage with said edge (39).
- Closure system (1), according to one or more of the previous claims, characterised in that said disc-shaped upper portion (17) comprises, at its face that faces said opening (13) of said inner capsule (9), a plurality of tabs (38) projecting axially towards the edge (39) of said opening (13) and configured to engage with said edge (39) and folded around said edge (39) of said opening (13).
- Closure system (1), according to one or more of the previous claims, characterised in that a tamper-evident ring (43) is associated with said outer capsule (15).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102016000119044A IT201600119044A1 (en) | 2016-11-24 | 2016-11-24 | CLOSING SYSTEM FOR BOTTLES CONTAINING LIOFILIZED OR LIQUID PRODUCTS, PARTICULARLY INJECTABLE OR PERFUSIONAL PHARMACEUTICAL PRODUCTS. |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3326932A1 true EP3326932A1 (en) | 2018-05-30 |
EP3326932B1 EP3326932B1 (en) | 2019-09-11 |
Family
ID=58401973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17194211.3A Active EP3326932B1 (en) | 2016-11-24 | 2017-09-29 | Closure system for bottles containing lyophilized or liquid products, particularly injectable or perfusable pharmaceutical products |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3326932B1 (en) |
ES (1) | ES2761354T3 (en) |
IT (1) | IT201600119044A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021016328A1 (en) * | 2019-07-23 | 2021-01-28 | West Pharmaceutical Services, Inc. | Vial closure assembly |
WO2021144511A1 (en) * | 2020-01-16 | 2021-07-22 | A. Raymond Et Cie | Locking cover for a container having a neck, with a cap having breakable securing tabs |
EP4085892A1 (en) | 2021-05-06 | 2022-11-09 | KAISHA PACKAGING Private Ltd. | Tamper evident plastic closure for vials for storing substances for medical or pharmaceutical applications and use thereof |
USD1006621S1 (en) | 2021-06-11 | 2023-12-05 | KAISHA PACKAGING Private Ltd. | Tamper evident plastic closure |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5080245A (en) * | 1990-03-22 | 1992-01-14 | The West Company Incorporated | Bidirectional scoring |
WO1997031839A1 (en) * | 1996-02-29 | 1997-09-04 | Bormioli Rocco & Figlio S.P.A. | A capsule for security closure of containers |
WO2011039004A1 (en) * | 2009-10-01 | 2011-04-07 | A. Raymond Et Cie | Locking cover for a vessel having a neck, including a cap having attachment tabs |
US20130245592A1 (en) * | 2012-03-16 | 2013-09-19 | Fisher Scientific Company L.L.C. | Chlorobutyl rubber-based self-resealing septum and closure assembly |
-
2016
- 2016-11-24 IT IT102016000119044A patent/IT201600119044A1/en unknown
-
2017
- 2017-09-29 ES ES17194211T patent/ES2761354T3/en active Active
- 2017-09-29 EP EP17194211.3A patent/EP3326932B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5080245A (en) * | 1990-03-22 | 1992-01-14 | The West Company Incorporated | Bidirectional scoring |
WO1997031839A1 (en) * | 1996-02-29 | 1997-09-04 | Bormioli Rocco & Figlio S.P.A. | A capsule for security closure of containers |
WO2011039004A1 (en) * | 2009-10-01 | 2011-04-07 | A. Raymond Et Cie | Locking cover for a vessel having a neck, including a cap having attachment tabs |
US20130245592A1 (en) * | 2012-03-16 | 2013-09-19 | Fisher Scientific Company L.L.C. | Chlorobutyl rubber-based self-resealing septum and closure assembly |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021016328A1 (en) * | 2019-07-23 | 2021-01-28 | West Pharmaceutical Services, Inc. | Vial closure assembly |
CN114206746A (en) * | 2019-07-23 | 2022-03-18 | 西医药服务有限公司 | Vial closure assembly |
US12071279B2 (en) | 2019-07-23 | 2024-08-27 | West Pharmaceutical Services, Inc. | Vial closure assembly |
WO2021144511A1 (en) * | 2020-01-16 | 2021-07-22 | A. Raymond Et Cie | Locking cover for a container having a neck, with a cap having breakable securing tabs |
FR3106339A1 (en) * | 2020-01-16 | 2021-07-23 | A. Raymond Et Cie | Locking cap for collared container with a capsule with securing tabs |
EP4085892A1 (en) | 2021-05-06 | 2022-11-09 | KAISHA PACKAGING Private Ltd. | Tamper evident plastic closure for vials for storing substances for medical or pharmaceutical applications and use thereof |
US11850210B2 (en) | 2021-05-06 | 2023-12-26 | Kaisha Packaging Private Limited | Tamper evident plastic closure for vials for storing substances for medical or pharmaceutical applications and use thereof |
USD1006621S1 (en) | 2021-06-11 | 2023-12-05 | KAISHA PACKAGING Private Ltd. | Tamper evident plastic closure |
Also Published As
Publication number | Publication date |
---|---|
EP3326932B1 (en) | 2019-09-11 |
ES2761354T3 (en) | 2020-05-19 |
IT201600119044A1 (en) | 2018-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3326932B1 (en) | Closure system for bottles containing lyophilized or liquid products, particularly injectable or perfusable pharmaceutical products | |
EP3313747B1 (en) | Closing assembly for a bottle, associated bottle and assembly method | |
US3393817A (en) | Sealed feeding bottle assembly | |
JP6309890B2 (en) | Closing device and container having the device | |
EP3042862B1 (en) | Cap for vial | |
US5269429A (en) | Closure cap for infusion or transfusion bottles | |
EP0634340B1 (en) | Bottle for preserving in a separated condition substance to be mixed together before dispensing | |
MX2014009127A (en) | Locking device for a cap. | |
SE450567B (en) | CONTAINER CLOSURE | |
CA2931014A1 (en) | Closure assembly for bottle and assembly method | |
GB1580306A (en) | Airtight container | |
EP3615447B1 (en) | Safety capsule with strip for preventing extraction | |
AU2018390412A1 (en) | Lid for containers under vacuum | |
US9265696B2 (en) | Closure cap | |
RU2461500C2 (en) | Container and method of its fabrication | |
EP4296187A1 (en) | Closure device, particularly for bottles of lyophilized products, and process for closing a bottle of lyophilized products | |
CN112638347A (en) | Device for temporarily connecting two containers | |
IE41596B1 (en) | Over cap | |
AU2015341110B2 (en) | Container comprising a single-piece head section | |
JP5083851B1 (en) | Pilfer proof cap with TE cover | |
EP3296224B1 (en) | A cap and neck assembly for a food package | |
JP6429594B2 (en) | Container with tamper-evident prevention mechanism | |
KR20100004811U (en) | Cosmetic vessel with an airtight sealed structure | |
WO2001083314A1 (en) | Bottle and closure assembly for medicaments and phleboclysis | |
WO2022172101A1 (en) | Bottle for a container for parenterally administrable pharmaceutical products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: RIZZARDI, MARCO MARIA CARLO Inventor name: ADDABBO, GIUSEPPE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20181114 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20190405 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1178174 Country of ref document: AT Kind code of ref document: T Effective date: 20190915 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017006922 Country of ref document: DE Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20190911 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191211 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191211 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191212 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1178174 Country of ref document: AT Kind code of ref document: T Effective date: 20190911 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200113 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2761354 Country of ref document: ES Kind code of ref document: T3 Effective date: 20200519 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200224 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602017006922 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG2D | Information on lapse in contracting state deleted |
Ref country code: IS |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190929 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190929 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200112 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20190930 |
|
26N | No opposition filed |
Effective date: 20200615 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190930 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20170929 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200930 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200930 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20210929 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190911 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210929 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230518 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230911 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20231006 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240806 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240808 Year of fee payment: 8 |